Wednesday, 28 October 2026European Markets

THUNDERBIRD Stock Bullish Momentum With A 20% Jump In The Last 10 Sessions

Loading stream...

Thunderbird Resorts Inc. (AEX-Index: TBIRD.AS) shares have experienced an astonishing 20.22% gain over 10 sessions, rising from EUR0.09 to EUR0.11. This remarkable turnaround occurred despite a downward trend observed within the AEX-Index that saw it decrease 1.62% to EUR765.16 in that same timeframe.

Investor Interest and Operations

Thunderbird Resorts' gaming, hospitality and real estate operations in Nicaragua and Peru have experienced increased market interest despite overall economic sentiment. Their diverse operations, which include table and slot games, sportsbooks and real estate investments provide a solid basis for expanding revenue growth.

Earnings Performance

Thunderbird Resorts stands out as an indicator of its performance with an earnings per share (EPS) ratio of EUR0.01, meaning for every share held, the earnings during the past year total EUR0.01 per share.

Investment Value

Thunderbird currently holds a trailing twelve months price-to-earnings (P/E) ratio of 10.5, meaning an investment in its stock would result in payments equaling EUR10.5 for every euro of annual earnings.

Trading Volume

Thunderbird reported its most recent trading volume as 48,500, which is 23.82% lower than its average volume of 63,665. This could suggest decreased investor enthusiasm or reduced trading activity.

Volatility and Momentum Indicators

Looking at recent volatility, Thunderbird stock fluctuated with an intraday variance of negative 1.01% over the last week and positive variations of 1.07% and 5.95% during months and quarters respectively; its highest average weekly volatility reached 6.06%.

The stochastic oscillator, a popular momentum indicator used by investors, indicates Thunderbird stock as being oversold (=20). This could signal potential trend reversals or value investment opportunities; however, comprehensive analysis should always be performed rather than solely relying on a single indicator.

More news about THUNDERBIRD (TBIRD.AS).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biotech Catalyst Window: ESMO Data, the Ivonescimab PDUFA and Small-Cap Delistings
Mid-October to November 2026 is a dense catalyst period for clinical-stage biotech. Positive late-stage readouts (ALOFT-IPF, TELIGAN, MIUDELLA, the duvakitug extension) and the ESMO 2026 presentations lead up to the FDA's 14 November PDUFA date for the ivonescimab BLA. At the opposite end of the market, Spago Nanomedical is moving to delist from Nasdaq First North, which shows how hard it is for micro-cap developers to fund themselves. Value is concentrating in companies with late-stage data and near-term regulatory outcomes.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,500 source documents archived
Query this data → isubstrate.com